A Comprehensive Review on Sustainable Molecular Pharming of Plant-based Pharmaceuticals: Challenges and Future Prospects
Medicinal plants have historically played a vital role in healthcare, with approximately 80% of the global population relying on traditional remedies. The emergence of molecular pharming, or biopharming, marks a significant advancement in biotechnology, enabling genetically modified plants to serve as biofactories to produce important therapeutic proteins. Molecular pharming is cost-effective and scalable compared to conventional systems, such as mammalian cell cultures. Plant genetic transformation techniques, including the use of Agrobacterium tumefaciens for gene insertion, have facilitated the expression of diverse proteins in a range of plant species. The integration of functional genomics has significantly advanced our understanding of the genetic and epigenetic mechanisms regulating secondary metabolite synthesis in plants. Techniques such as genome mining and high-throughput sequencing have facilitated the identification of biosynthetic gene clusters, leading to the discovery of novel therapeutic agents. Additionally, multiplex genome editing technologies, notably CRISPR-Cas9, have revolutionised the production of biologically active molecules, including therapeutic proteins, vaccines, antibodies, and industrial enzymes in plants. Nanoparticles also play a crucial role in molecular pharming, serving as versatile carriers for gene delivery and protein encapsulation, thereby improving transformation efficiency and product monitoring. This review explores the role of molecular pharming, or biopharming, as a cutting-edge biotechnological approach that utilises genetically modified plants to produce valuable proteins, therapeutic enzymes and other biologically active compounds. Major Findings: The article explores the role of molecular pharming, or biopharming, as a cutting-edge biotechnological approach that utilises genetically modified plants to produce valuable proteins, therapeutic enzymes and other biologically active compounds. The article also addresses v